EphA5 Expression Predicts Better Survival Despite an Association with Proliferative Activity in Endometrial Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Eph receptor A5 (EphA5), a receptor tyrosine kinase, is involved in various cancers, but its role in endometrial cancer (EC) is not well understood.
• Investigating EphA5 in EC is crucial for understanding its potential as a prognostic marker.

Purpose of the Study:

• To determine the clinicopathological significance of EphA5 expression in endometrial cancer.
• To explore the association between EphA5 and markers of proliferation and metabolism in EC.

Main Methods:

• Retrospective analysis of 75 treatment-naïve EC tissue samples using immunohistochemistry and H-score quantification.
• Logistic regression and Kaplan-Meier analyses were employed to assess associations with clinicopathological parameters and survival outcomes.
• Stage-specific correlation analyses were performed to investigate biomarker interactions.

Main Results:

• High EphA5 expression correlated with increased Ki-67 (proliferation marker) and decreased pAMPK (metabolic stress marker).
• Patients with high EphA5 levels exhibited significantly better overall survival probabilities.
• EphA5 expression was linked to proliferation in early-stage EC and epithelial-mesenchymal transition in advanced stages.

Conclusions:

• EphA5 functions as a context-dependent biomarker in endometrial cancer.
• Despite associations with proliferation and metabolic pathways, high EphA5 expression indicates a favorable prognosis in EC.